Drug name - Iclusig

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8114874 TAKEDA PHARMS USA Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors
Jan, 2027

(4 years from now)

US9493470 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(11 years from now)

US11192897 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(11 years from now)

CN103435595A TAKEDA PHARMS USA Acetylenic Heteroaryl Compounds
Jun, 2015

(7 years ago)

CN101489558A TAKEDA PHARMS USA Acetylenic Heteroaryl Compounds
Aug, 2015

(7 years ago)

CN101490053B TAKEDA PHARMS USA Single-Ring Heteroaryl Compounds
Apr, 2021

(1 year, 5 months ago)

CN101490053A TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Apr, 2021

(1 year, 5 months ago)

CN103467385A TAKEDA PHARMS USA Single-Ring Heteroaryl Compounds
Apr, 2021

(1 year, 5 months ago)

CN103467385B TAKEDA PHARMS USA Monocyclic Heteroaryl Compounds
Apr, 2021

(1 year, 5 months ago)

CN103044432A TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

CN101389338A TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

CN101389338B TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

CN103044432B TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

IN200802328P2 TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

IN267087B TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

EP2495016B1 TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

EP2495016A1 TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

EP3417912A1 TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

EP3417912B1 TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

EP2024366A2 TAKEDA PHARMS USA Monocyclic Heteroaryl Compounds
May, 2027

(4 years from now)

EP2024366B1 TAKEDA PHARMS USA Monocyclic Heteroaryl Compounds
May, 2027

(4 years from now)

EP2024366A4 TAKEDA PHARMS USA Monocyclic Heteroaryl Compounds
May, 2027

(4 years from now)

EP1973545A2 TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Jul, 2028

(5 years from now)

EP1973545B1 TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Jul, 2028

(5 years from now)

EP1973545A4 TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Jul, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9029533 TAKEDA PHARMS USA Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors Dec, 2026

(4 years from now)

US11192895 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Dec, 2033

(11 years from now)

Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient

Treatment: A method of treating chronic myelogenous leukemia; a method for treating philadelphia chromosome positive acute lymphoblastic leukemia; a method for treating leukemia resulting from a mutation in the bcr-abl kinase domain; a method for the treatment of leukemias; a method for treating acute lymphoblastic leukemia; A method for treating philadelphia chromosome positive acute lymphoblastic leukemia; a method for treating leukemia resulting from a mutation in the bcr-abl kinase domain; a method for treating chronic myeloid leukemia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE TABLET;ORAL Prescription
EQ 15MG BASE TABLET;ORAL Prescription
EQ 30MG BASE TABLET;ORAL Prescription
EQ 45MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.